Fig. 1

Neutrophil-to-lymphocyte ratio (NLR) at start of anti-PD-1/PD-L1 therapy by a IMDC risk groups and b Histology (clear cell RCC, ccRCC; non-clear cell RCC, nccRCC)
Neutrophil-to-lymphocyte ratio (NLR) at start of anti-PD-1/PD-L1 therapy by a IMDC risk groups and b Histology (clear cell RCC, ccRCC; non-clear cell RCC, nccRCC)